Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
Eldani C, Kostine M, Faure M, Lazaro E, Rigothier C, Hiriart JB, Teulières B, Poullenot F, Haissaguerre M, Zysman M, Veillon R, Vergnenegre C, Issa N, Domblides C, Mary-Prey S, Beylot-Barry M, Pham-Ledard A, Dutriaux C, Sole G, Duval F, Gerard E. Eldani C, et al. Among authors: mary prey s. Front Oncol. 2024 Jul 8;14:1403658. doi: 10.3389/fonc.2024.1403658. eCollection 2024. Front Oncol. 2024. PMID: 39040444 Free PMC article.
Use of spironolactone for the treatment of acne in adolescent girls.
Canu D, Mary-Prey S, Legrand A, Leauté-Labreze C. Canu D, et al. Among authors: mary prey s. Ann Dermatol Venereol. 2024 Jun;151(2):103281. doi: 10.1016/j.annder.2024.103281. Epub 2024 May 22. Ann Dermatol Venereol. 2024. PMID: 38781891 No abstract available.
Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
Connell E, Gerard É, Oules B, Brunet-Possenti F, Lamoureux A, Bonnefille H, Mary-Prey S, Carrasquilla A, Mouret S, Kramkimel N, Lesage C, Stoebner PE, Bartoli A, Monestier S, Correard F, Gros A, Jeanson A, Ouafik L, Gaudy-Marqueste C, Tomasini P, Charles J, Amini-Adle M, Malissen N. Connell E, et al. Among authors: mary prey s. Oncologist. 2024 Sep 6;29(9):e1180-e1188. doi: 10.1093/oncolo/oyae085. Oncologist. 2024. PMID: 38761384 Free PMC article.
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A; GCC group Groupe Cancérologie Cutanée – Cutaneous Oncology Group, the Ethical Group of the Société Française de Dermatologie French Dermatology Group. Amini-Adle M, et al. Among authors: mary prey s. Ann Dermatol Venereol. 2024 Mar;151(1):103243. doi: 10.1016/j.annder.2023.103243. Epub 2024 Feb 6. Ann Dermatol Venereol. 2024. PMID: 38325268 No abstract available.